We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Celestial Labs is a drone display company that combines advanced technology with organic performance. The company's proprietary 'Skytheatre' display is a dynamic, safe and green alternative to carbon-intensive fireworks and represents a new frontier for the live event industry. Composed of a creative collective of award-winning filmmakers, musicians, developers, entrepreneurs, and storytellers, the company is constantly pushing the boundaries of drone display innovation, where technology meets imagination. The Human Support division of Celestial is a not-for-profit initiative that aims to lift the spirits of those who witness Celestial's displays whilst imparting crucial information. The company aims to enlist the support and guidance of city leadership partners, industrial conglomerates, and seek grant funding.
days to go: Stretch investment: Withheld
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001
Active Food Systems, trading as Synergy Grill, has developed and patented innovative and commercial cooking technology for the food and hospitality industry. Its ‘Fat Atomising Grill' makes cleaning quick and easy while delivering cost savings through a 59% reduction in fuel consumption. The company has sold 2000+ units of the grill to entities like Whitbread, Greene King, Marriott, Radisson and Marstons among others. Synergy Grill asserts that its performance in the first half of the year has been profitable despite COVID-19. They have contracts with reputed organisations like Whitbread and Marstons have generated revenues of £970,000. The company is in conversation with over 50 pubs and restaurants including product trials with Nandos, Weatherspoons and Mitchell Butler that are interested in its product. It will use the investment to grow its business across different verticals.
days to go: Expired investment: £316,488
Garbanzo Snacks is a profitable businesses, currently selling their chickpeas with a sprinkling of flavour in 725 Holland and Barrett stores. They use 100% chickpeas with minimal processing, this keeps the products as pure and unadulterated as possible. 
days to go: Expired investment: Withheld
EarlyBird have created a number of different healthy snack packs, all made with fresh ingredients. EarlyBird deliver their snacks straight to your door meaning you don't have to leave the comfort of your home. 
days to go: Expired investment: £168,000
Sense Products is a food supplement company that currently have 5 products on the market; Sense for a night out (alcohol), Sense for nicotine lovers (smokers), Sense for cholesterol, Sense for city living (busy lives) and Sense for weight warriors.
days to go: Expired investment: £200,000
Run3D is a biotechnology company that has developed a 3D gait analysis system with the aim to help people identify injuries, deliver better performance, and make better running decisions. 3D gait analysis involves using infrared cameras to track positions of small reflective markers attached to a person in motion, capturing measurable data to help quantify a person's risk of injury, biomechanical efficiency, performance, footwear, and recommend proper diagnosis where necessary. The company plans to use the investment to grow its business.
days to go: Expired investment: Withheld
Intelligent Health aim to get the whole community active by providing games and incentives such as ''beat the street''. By providing schools and communities with friendly competition to walk and cycle more by tapping their cards on ''beat boxes'', and with prizes and league tables on offer, Intelligent health are bringing communities together. 
days to go: Expired investment: £700,000
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph